Multicomponent T2 analysis (mcT2) can provide a clinically-useful myelin biomarker in vivo. Its clinical applicability, however, is hindered by lack of gold standard technique that can overcome the ambiguity of fitting several T2 components to a single experimental signal. In this study we aimed to validate the utility of a novel data-driven mcT2 mapping algorithm for quantifying myelin content. To that end, we applied the mcT2 algorithm to 14 mice divided into two groups of mice: cuprizone-induced demyelination model, and controls. Results show excellent agreement between the mcT2 based myelin biomarker and ground truth quantification of myelin from immunohistochemical staining.
This abstract and the presentation materials are available to members only; a login is required.